Analyst
TD Cowan
Equibles does not estimate personal net worth.
Tyler Van Buren is recorded as Analyst at TD Cowan. Tyler Van Buren has spoken on 4 earnings calls and 2 other investor events across 5 companies, most recently for Gilead Sciences, Inc. on August 4, 2026. Those appearances were for Gilead Sciences, Inc. (GILD), Regeneron Pharmaceuticals, Inc. (REGN), Summit Therapeutics Inc. (SMMT), Arcutis Biotherapeutics, Inc. (ARQT) and Iovance Biotherapeutics, Inc. (IOVA). The companies whose calls Tyler Van Buren spoke on are classified in the Healthcare sector.
“It's impressive to see the continued performance of the prep franchise overall between both Discovery and Yes2Go. But to be specific, could you help us better understand the growing delta in recent Yes2Go prescription trends versus sales that are being reported by outlets like IQBIA.”
“So can you provide additional details on the ongoing ILEA HD pre-filled syringe review with hopeful approval by year-end now? And when you say working with multiple contract manufacturers, does that mean there is now a third CMO in the mix?”
“For our next session, it's a privilege to have a fireside chat with Gilead Management. And from Gilead, it's my pleasure to introduce Joanna Mercier, Chief Commercial Officer of Gilead.”
“For our next session, I'm very excited to host Arcudis for a hybrid presentation and fireside chat style Q&A. It's my pleasure to introduce Frank Watanabe, the CEO, and Todd Edwards, the Chief Commercial Officer of Arcudis.”
TD Cowan
Analyst
Transcript header (unverified)
Drug Manufacturers - General · Healthcare
